<DOC>
	<DOCNO>NCT01281800</DOCNO>
	<brief_summary>This randomise Phase II clinical trial ass compare efficacy safety profile cisplatin pemetrexed cisplatin low-dose gemcitabine long infusion .</brief_summary>
	<brief_title>Cisplatin With Alimta Gemcitabine Long Infusion Mesothelioma</brief_title>
	<detailed_description>Combination pemetrexed cisplatin consider standard systemic treatment mesothelioma . Three argument position : 1 . Pemetrexed combination cisplatin register mesothelioma basis superiority cisplatin alone , clearly suboptimal control arm ; 2 . Several Phase II trial gemcitabine standard dos low-dose long infusion combination cisplatin show least comparable activity ; 3 . Due high cost , pemetrexed available many patient country limit health care resource . During past five year , research team Ljubljana conduct Phase II trial low-dose gemcitabine ( 250 mg/m2 ) 6-hours infusion cisplatin patient mesothelioma . In unselected population patient include poor performance status , elderly , patient advance extrathoracic disease patient progression previous chemotherapy , response rate 54 % , median survival 16.5 month . On basis favourable experience search cost-effective treatment mesothelioma , propose randomise Phase II clinical trial compare efficacy safety profile cisplatin pemetrexed cisplatin low-dose gemcitabine long infusion . The primary endpoint response rate time progression ; secondary endpoint survival , toxicity quality life .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>histologically proven mesothelioma . While local histopathology exam sufficient register patient trial , biopsy subject central review ( please see Section 5.3 . ) history malignancy ; complete remission &gt; 3 year previously treat malignancy ; chemonaive ; performance status ≥ 70 % ( Karnofsky ) ; ECOG 0 2 ; peripheral neuropathy grade 2 ( common toxicity criterion CTC , NCI ) , unless mechanical origin ; vascular disease grade 2 ( NCI CTC ver.3 ) ; hemoglobin &gt; 100 g/L ; neutrophil &gt; 2.0 g/L ; platelet &gt; 100 x 109 /L ; kidney function : creatinine within normal limit + ECC &gt; 60 mL/min ; ECC &gt; 100 mL/min ; liver function : bilirubin &lt; 1.25 x UNL ; AST/ALT &lt; 2 x UNL ; cardiac compensation ; active infection serious concomitant disease ; woman pregnant patient 's understanding disease treatment write informed consent . • significant medical comorbidity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>